TOP TEN perturbations for 39628_at (Homo sapiens)
Organism: Homo sapiens
Gene: 39628_at
Selected probe(set): 221808_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array
Expression of 39628_at (221808_at) across 6674 perturbations tested by GENEVESTIGATOR:
echinomycin study 1 / deferoxamine study 5
Relative Expression (log2-ratio):-3.9173927Number of Samples:3 / 3
| Experimental | echinomycin study 1 |
| Echinomycin (100nM; 2h) treated human astroglioma (U251) cells, stimulated with deferoxamine (DFO; 300mM; 16h). ATC code:--- | |
| Control | deferoxamine study 5 |
| Untreated human astroglioma (U251) cells, stimulated with deferoxamine (DFO; 300mM; 16h). ATC code: |
dendritic cell study 7 (IL-4 mddc) / dendritic cell study 7 (IL-15 mddc)
Relative Expression (log2-ratio):3.0264473Number of Samples:3 / 3
| Experimental | dendritic cell study 7 (IL-4 mddc) |
| Mature IL-4 dendritic cells differentiated from CD14+ monocytes obtained from healthy donors. Monocytes were seeded in RPMI and supplemented with 2.5 % heat-inactivated human AB serum. Monocytes were cultured with 800 IU/mL granulocyte macrophage colony-stimulating factor and 20 ng/mL IL-4 in order to generate immature IL-4 DCs. Conventional maturation cocktail, comprising 10 ng/mL tumor necrosis factor-α, 10 ng/mL interleukin-1β, 15 ng/ml interleukin-6 and 1 µg/mL prostaglandin E2 was added for 48 hours. CD14+ monocytes were isolated from peripheral blood mononuclear cells (PBMC) by Ficoll density gradient centrifugation and purified by positive magnetic cell selection. | |
| Control | dendritic cell study 7 (IL-15 mddc) |
| Mature IL-15 dendritic cells differentiated from CD14+ monocytes obtained from healthy donors. Monocytes were seeded in RPMI and supplemented with 2.5 % heat-inactivated human AB serum. Differentiation was induced with 800 IU/mL granulocyte macrophage colony-stimulating factor and 200 ng/mL IL-15 to obtain immature IL-15 DCs. A TLR-activating maturation cocktail, comprising 3 µg/mL R848, 2.5 ng/mL tumor necrosis factor-α, 250 ng/mL interferon-γ and 1 µg/mL prostaglandin E2 was added after 24-48 hours of differentiation for 18-20 hours. CD14+ monocytes were isolated from peripheral blood mononuclear cells (PBMC) by Ficoll density gradient centrifugation and purified by positive magnetic cell selection. |
dendritic cell study 6 (gardiquimod; RN486) / dendritic cell study 6 (CpG A; RN486)
Relative Expression (log2-ratio):2.7602081Number of Samples:4 / 4
| Experimental | dendritic cell study 6 (gardiquimod; RN486) |
| Plasmacytoid dendritic cells (pDCs) collected from blood of healthy donors and treated with gardiquimod (TLR7 agonist) and RN486 (Bruton’s tyrosine kinase; BTK inhibitor) for 3 hours. pDCs were sorted as CD303+, CD123+, CD45+, CD69+, CD40+, CD86+. | |
| Control | dendritic cell study 6 (CpG A; RN486) |
| Plasmacytoid dendritic cells (pDCs) collected from blood of healthy donors and treated with CpG-A ODN2216 Class A (TLR9 agonist) and RN486 (Bruton’s tyrosine kinase; BTK inhibitor) for 3 hours. pDCs were sorted as CD303+, CD123+, CD45+, CD69+, CD40+, CD86+. |
kidney transplantation study 15 (8 week) / normal monocyte (CD14+) sample
Relative Expression (log2-ratio):-2.6658173Number of Samples:2 / 5
| Experimental | kidney transplantation study 15 (8 week) |
| CD14+ monocyte samples derived from kidney transplant patients 8 weeks post-transplantation. Samples were collected 8 week after transplantation and administration of immunosuppressive therapy (day 1-4: methylprednisolone (60 mg); 3 doses: rabbit polyclonal anti-thymocyte globulin (ThymoglobulinH; 6 mg/kg); mycophenolate mofetil (CellCeptH); and tacrolimus (PrografH). | |
| Control | normal monocyte (CD14+) sample |
| CD14+ monocyte samples derived from healthy control subjects. |
expO ovary cancer study 1 (malignant mixed Mullerian tumor; primary) / expO ovary cancer study 1 (endometrioid and clear cell adenocarcinoma; primary)
Relative Expression (log2-ratio):-2.4171057Number of Samples:3 / 2
| Experimental | expO ovary cancer study 1 (malignant mixed Mullerian tumor; primary) |
| Primary tumor tissue samples obtained from the ovary of patients with malignant mixed Mullerian tumor. | |
| Control | expO ovary cancer study 1 (endometrioid and clear cell adenocarcinoma; primary) |
| Primary tumor tissue samples obtained from the ovary of patients with endometrioid and clear cell adenocarcinoma. |
expO ovary cancer study 1 (malignant mixed Mullerian tumor; primary) / expO ovary cancer study 1 (clear cell adenocarcinoma, NOS; primary)
Relative Expression (log2-ratio):-2.2410889Number of Samples:3 / 12
| Experimental | expO ovary cancer study 1 (malignant mixed Mullerian tumor; primary) |
| Primary tumor tissue samples obtained from the ovary of patients with malignant mixed Mullerian tumor. | |
| Control | expO ovary cancer study 1 (clear cell adenocarcinoma, NOS; primary) |
| Primary tumor tissue samples obtained from the ovary of patients with clear cell adenocarcinoma (NOS). |
dendritic cell study 6 (gardiquimod; RN486) / dendritic cell study 6 (untreated)
Relative Expression (log2-ratio):2.2399416Number of Samples:4 / 8
| Experimental | dendritic cell study 6 (gardiquimod; RN486) |
| Plasmacytoid dendritic cells (pDCs) collected from blood of healthy donors and treated with gardiquimod (TLR7 agonist) and RN486 (Bruton’s tyrosine kinase; BTK inhibitor) for 3 hours. pDCs were sorted as CD303+, CD123+, CD45+, CD69+, CD40+, CD86+. | |
| Control | dendritic cell study 6 (untreated) |
| Plasmacytoid dendritic cells (pDCs) collected from blood of healthy donors. pDCs were sorted as CD303+, CD123+, CD45+, CD69+, CD40+, CD86+. |
dendritic cell study 6 (gardiquimod) / dendritic cell study 6 (untreated)
Relative Expression (log2-ratio):2.2199516Number of Samples:7 / 8
| Experimental | dendritic cell study 6 (gardiquimod) |
| Plasmacytoid dendritic cells (pDCs) collected from blood of healthy donors and treated with gardiquimod (TLR7 agonist) for 3 hours. pDCs were sorted as CD303+, CD123+, CD45+, CD69+, CD40+, CD86+. | |
| Control | dendritic cell study 6 (untreated) |
| Plasmacytoid dendritic cells (pDCs) collected from blood of healthy donors. pDCs were sorted as CD303+, CD123+, CD45+, CD69+, CD40+, CD86+. |
C. pneumoniae study 1 / uninfected monocyte-derived dendritic cell sample
Relative Expression (log2-ratio):2.1672363Number of Samples:2 / 2
| Experimental | C. pneumoniae study 1 |
| Monocyte-derived dendritic cells from healthy donors were infected with Chlamydia pneumoniae at a multiplicity of infection of 5 for 72 h. | |
| Control | uninfected monocyte-derived dendritic cell sample |
| Uninfected monocyte-derived dendritic cells from healthy donors. |
R547 study 1 (24h) / vehicle (DMSO) treated DU145 cell sample
Relative Expression (log2-ratio):-2.1286402Number of Samples:2 / 4
| Experimental | R547 study 1 (24h) |
| Human prostate carcinoma metastatic cell line DU145 treated with the CDK inhibitor R547 [4-amino-2-(1-methanesulfonylpiperidin-4-ylamino) pyrimidin-5-yl]-(2, 3-difluoro-6-methoxyphenyl)methanone (Hoffmann-La Roche compound) for 24 hours at a 3xIC90 concentration of 5.1 μmol/L. ATC code:--- | |
| Control | vehicle (DMSO) treated DU145 cell sample |
| Human prostate carcinoma metastatic cell line DU145 treated with vehicle (DMSO) for 24 hours. |